FDA approves Vyvanse (lisdexamfetamine dimesylate) to treat Binge Eating Disorder-Shire
Shire plc has announced that the FDA approved Vyvanse (lisdexamfetamine dimesylate) Capsules (CII), the first and only medication for the treatment of moderate to severe Binge Eating Disorder (B.E.D.) in adults, shown to significantly reduce the mean number of binge days per week. Vyvanse is not indicated or recommended for weight loss or the treatment of obesity. Other sympathomimetic drugs used for weight loss have been associated with serious cardiovascular reactions.
Comment: The efficacy of Vyvanse in treating binge-eating disorder was shown in two clinical studies that included 724 adults with moderate-to-severe Binge-Eating Disorder. In the studies, participants taking Vyvanse experienced a decrease in the number of binge eating days per week and had fewer obsessive-compulsive binge eating behaviors compared to those on the inactive pill (placebo).
Vyvanse was approved in 2007 as a once-daily medication to treat Attention Deficit Hyperactivity Disorder in patients ages 6 and older. Vyvanse is a Schedule II controlled substance because it has high potential for abuse, with use potentially leading to dependence.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins